1-Acetyl-5-MeO-DMT, also known as "methyl amide 5-MeO-DMT" or as 1-acetyl-5-methoxy-N,N-dimethyltryptamine, is a psychedelic drug of the tryptamine and 5-methoxytryptamine families related to 5-MeO-DMT. It is the 1-acetyl derivative of 5-MeO-DMT. The drug is a prodrug of 5-MeO-DMT with modified pharmacokinetic properties compared to 5-MeO-DMT in rodents. It is assumed to be cleaved into 5-MeO-DMT by amidase enzymes. Various analogues of 1-acetyl-5-MeO-DMT that are likewise 5-MeO-DMT or dimethyltryptamine (DMT) prodrugs have also been described and have shown widely varying pharmacokinetic parameters, for instance half-life. 1-Acetyl-5-MeO-DMT was first described in the literature in a patent by Terran Biosciences in 2023. It has been one of the major prodrug compounds highlighted from the patent.
See also Substituted tryptamine 1-Benzoyl-DMT (1-Bz-DMT) NBoc-DMT (N′-tert-butoxycarbonyl-DMT) N-Phosphonooxymethyl-DMT (N-POM-DMT) ALD-52 (1-acetyl-LSD; 1A-LSD)
References